Biotech Values

[walldiver]

<<As a layman looking at these curves, I am not overly impressed, but I do come away with the impression that Provenge is probably somewhat effective in helping long term survival. What am I missing?>>

Approximately 75% of the placebo arm consisted of patients who opted to cross over and receive Provenge after progression. It would be interesting to see three curves for each trial...treatment curve, crossover curve, non-crossover curve.

The two-year data from the 9901 trial had a 2.4-month median survival advantage for Provenge vs the placebo crossovers, and a 7.0-month benefit for Provenge vs the placebo decliners.